CLBR001 + SWI019 *

CLBR001 is a Chimeric antigen receptor T (CAR-T) cell product that comprises the patient’s T cells and a novel “switchable” chimeric antigen receptor (sCAR-T).  SWI019 is an Antibody Fab-based biologic, called the “switch”, which targets the B cell antigen CD19.   CLBR001 + SWI019 are being developed by Calibr in a Phase I first in patient clinical trial for patients with B cell malignancies.

AbbVie and Calibr will also work together to develop novel switchable T-cell therapies directed to various tumor targets identified by AbbVie. AbbVie also has option to license certain existing Calibr cell therapy programs under development for hematological and solid cancers, including Calibr's lead program.

Type of Molecule

Biologic

Target

CD19

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Hematologic Tumors n/a
Phase 1